Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
ACTIVE_NOT_RECRUITING
PHASE1
223 participants
INTERVENTIONAL
2016-11-21
2026-08-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Study of LY2157299 in Japanese Participants With Cancer
NCT01722825
A Study of LY3039478 in Participants With Advanced or Metastatic Solid Tumors
NCT02784795
A Study of LY3039478 in Japanese Participants With Advanced Solid Tumors
NCT02836600
A Study of YL242 in Subjects With Advanced Solid Tumors
NCT07197827
A Study of the Safety and Efficacy of Atezolizumab Administered in Combination With Bevacizumab and/or Other Treatments in Participants With Solid Tumors
NCT02715531
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
NON_RANDOMIZED
PARALLEL
TREATMENT
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
LY3200882 Schedule 1 Escalation
LY3200882
Administered orally
LY3200882 Schedule 2 Escalation
LY3200882
Administered orally
LY3200882 Schedule 1 Expansion
LY3200882
Administered orally
LY3200882 Schedule 2 Expansion
LY3200882
Administered orally
LY3200882 + LY3300054
LY3200882
Administered orally
LY3300054
Administered intravenously
LY3200882 + Gemcitabine + nab-Paclitaxel
LY3200882
Administered orally
Gemcitabine
Administered intravenously
nab-Paclitaxel
Administered intravenously
LY3200882 + Cisplatin + Radiation
LY3200882
Administered orally
Cisplatin
Administered intravenously
Intensity Modulated Radiotherapy
Japanese Arm LY3200882
LY3200882
Administered orally
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
LY3200882
Administered orally
LY3300054
Administered intravenously
Gemcitabine
Administered intravenously
nab-Paclitaxel
Administered intravenously
Cisplatin
Administered intravenously
Intensity Modulated Radiotherapy
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Have adequate organ function.
* Have Eastern Cooperative Oncology Group (ECOG) scale performance status of 0 or 1.
* Are able to swallow capsules and tablets.
Exclusion Criteria
* Have a serious concomitant systemic disorder.
* Have acute leukemia.
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Eli Lilly and Company
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 9 AM - 5 PM Eastern time (UTC/GMT - 5 hours, EST)
Role: STUDY_DIRECTOR
Eli Lilly and Company
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
University of Louisville
Louisville, Kentucky, United States
Weill Cornell Medical College
New York, New York, United States
University of Texas MD Anderson Cancer Center
Houston, Texas, United States
Calvary Mater Newcastle
Newcastle, New South Wales, Australia
St Vincent's Hospital Sydney
Sydney, New South Wales, Australia
Greenslopes Private Hospital
Greenslopes, Queensland, Australia
Princess Margaret Hospital (Ontario)
Lai Chi Kok, Kowloon, Canada
Hopital Saint-Louis
Paris, Cedex 10, France
CHRU de Lille
Lille, , France
Gustave Roussy
Villejuif, , France
Universitätsklinikum Würzburg A. ö. R.
Würzburg, Bavaria, Germany
Charité Campus Virchow-Klinikum
Berlin, , Germany
Istituto Clinico Humanitas
Rozzano, Milano, Italy
Ospedale Policlinico Giambattista Rossi, Borgo Roma
Verona, , Italy
National Cancer Center Hospital
Chuo-Ku, Tokyo, Japan
Hospital Universitari Vall d'Hebron
Barcelona, , Spain
Hospital Universitario 12 de Octubre
Madrid, , Spain
Hospital Clínico Universitario de Valencia
Valencia, , Spain
Countries
Review the countries where the study has at least one active or historical site.
References
Explore related publications, articles, or registry entries linked to this study.
Yap TA, Vieito M, Baldini C, Sepulveda-Sanchez JM, Kondo S, Simonelli M, Cosman R, van der Westhuizen A, Atkinson V, Carpentier AF, Lohr M, Redman R, Mason W, Cervantes A, Le Rhun E, Ochsenreither S, Warren L, Zhao Y, Callies S, Estrem ST, Man M, Gandhi L, Avsar E, Melisi D. First-In-Human Phase I Study of a Next-Generation, Oral, TGFbeta Receptor 1 Inhibitor, LY3200882, in Patients with Advanced Cancer. Clin Cancer Res. 2021 Dec 15;27(24):6666-6676. doi: 10.1158/1078-0432.CCR-21-1504. Epub 2021 Sep 21.
Related Links
Access external resources that provide additional context or updates about the study.
Click here for more information about this study: A Study of LY3200882 in Participants With Solid Tumors
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
I8X-MC-JECA
Identifier Type: OTHER
Identifier Source: secondary_id
2016-001431-12
Identifier Type: EUDRACT_NUMBER
Identifier Source: secondary_id
16185
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.